Option chain shows key data for Assembly Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Assembly Biosciences.

Assembly Biosciences (NASDAQ:ASMB) Stock, Option Chain

Assembly Biosciences

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

General

ASMB

Assembly Biosciences reported interim results from its Phase 1a study of ABI-5366, a long-acting HSV inhibitor for recurrent genital herpes. The drug showed a favorable safety profile and achieved target plasma concentrations for antiviral efficacy.

Assembly Biosciences&#39; Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED)

Coins,Money,Increase,To,Profit,For,Concept,Investment,Fund,Finance

Long Ideas

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

AMSWA

TTSH

Insiders Buying American Software And 2 Other Stocks

Penny Stocks

Small Cap

Movers

ACHV

ATXI

BLBD

BRSH

CMND

CNTB

HCDI

HPCO

HRYU

ICVX

INAB

IONM

KAVL

ONTX

ORCL

SVMH

TENX

WULF

XCUR

Shares of  Icosavax, Inc.  (NASDAQ: ICVX) rose sharply in pre-market trading after AstraZeneca announced plans to buy Icosavax in a deal valued at up to $1.1 billion.

Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences Inc

Guidance

Lennar Expects Q1 Gross Margin To Be 19.0% - 19.25%; Says Will Not Guide To Full Year Gross Margin At This Time Until Having Better Sense Of Market Conditions

Lennar Expects To Deliver 17,000 - 17,500 Homes For Q1 And 86,000 - 88,000 Homes For 2025, Including Impact Of Rausch Coleman Acquisition

Federal Reserve Chair Jerome Powell adopted a hawkish stance during his Wednesday press conference after the December Fed meeting, sparking a market bloodbath as the New York session <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">headed to the close.</a>
Although the Federal Reserve lowered interest rates by 0.25% to a range of 4.25%-4.5%, as widely anticipated, the updated economic projections suggest just two potential rate cuts in 2025 — down from four projected in September and fewer than the three anticipated by markets before the meeting.
Powell described the shift as &#8220;a new phase&#8221; for monetary policy, emphasizing that after 100 basis points of rate cuts in 2024, rates are now significantly closer to a neutral stance. 
Stocks tumbled across the board, the U.S. dollar soared to two-year highs and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) cratered over 5%, as investors digested the reality of a shift in the monetary policy stance by the Federal Reserve.
The CBOE Volatility Index, known as the VIX and Wall Street&#8217;s fear gauge, skyrocketed 58% to 25, reflecting a spike in investor uncertainty and heightened anxiety over the future of interest rates.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1024x557.png" alt="" class="wp-image-698569" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1024x557.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-300x163.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-768x418.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161-1536x836.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18161803/image-161.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Wall Street Wipeout: Major Indices Slammed</h3>
The Dow Jones Industrial Average, as tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), dropped 1,123 points, falling 2.6% to close at 42,326, marking its worst one-day drop since September 2022. Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) recorded the worst performance among blue-chip stocks, down 4.6%.
The S&amp;P 500 index — tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — fell 178 points, down 2.9% to 5,872, also marking its worst day since September 2022. Paycom Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) was the major laggard within the S&amp;P 500, down 10%.
The tech-heavy Nasdaq 100, tracked by the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), experienced an even sharper drop of 3.6%, closing at 21,209 as interest rate-sensitive technology stocks took a beating. Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) tumbled 8.1%, marking the worst performance within the Nasdaq 100.
Every Magnificent Seven company ended the day in the red, collectively erasing more than $600 billion in market value on Wednesday.
Small caps in the Russell 2000 posted the steepest losses, plummeting 4.7% to 2,225. With Wednesday&#8217;s move, the iShares Russell 2000 ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NASDAQ">IWM</a>) has fully erased the post-election rally.
All major U.S. equity sectors finished in the red. 
Consumer Discretionary stocks suffered the most, plunging 4.5%, followed by Real Estate, which dropped 4% as rising rates weigh heavily on growth-oriented and interest-rate-sensitive industries.
Technology, the largest sector by market capitalization, fell 3.2%, with chipmakers and software companies bearing the brunt of the selloff. 
Communications and Materials both declined 2.9%, while Financials dropped 3%, reflecting pressure across cyclical areas of the market.
Even traditionally defensive sectors failed to escape the selloff. Utilities and Consumer Staples fell 2.4% and 1.5%, respectively.
<h3 class="wp-block-heading">Dollar Surges To 2-Year Highs, Hammers Gold And Bitcoin</h3>
The U.S. dollar emerged as the day's clear winner, with the dollar index (DXY), followed by the Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), climbing 1.2% to reach its highest level since November 2022.
As the greenback rallied, gold failed to provide a safe haven, falling 2.1% to $2,580 per ounce, while silver dropped 3.5%.
Risk-off sentiment extended into alternative assets. Bitcoin plunged 5.5%, trading just above $101,500.
During the press conference, Powell was asked whether the U.S. government should consider building a strategic reserve of Bitcoin. Powell quickly dismissed the idea, making it clear that such a move is not on the Fed&#8217;s radar.
"We're not allowed to own Bitcoin," Powell said, emphasizing the legal and structural limitations of the Federal Reserve. "The Federal Reserve Act dictates what we can own, and we're not seeking any changes to that law."
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">Fed Slashes Interest Rates By 0.25% As Predicted: December Dot Plot Flags Only 2 Potential Cuts In 2025</a></li>
</ul>
Illustration generated with AI via Dall-E.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Large Cap

Broad U.S. Equity ETFs

Commodities

Currency ETFs

Econ #s

Economics

Federal Reserve

ETFs

$BTC

AMZN

SPDR Dow Jones Industrial Average ETF Trust

PAYC

TSLA

PowerShares DB US Dollar Index Bullish Fund

Powell Triggers Market Carnage: VIX Spikes 58%, Stocks Plummet, Dollar Hits 2-Year Highs, Bitcoin Nosedives

TURN

180 Degree Capital Says Press Release Issued By Marlton Contains Number Of Inaccuracies And Distortions

The proposed decision is scheduled to be voted on by the CPUC on January 16, 2025. When a final decision is issued by the CPUC, the new rates will be effective and retroactive to January 1, 2023.&nbsp;
As a result, the impact from retroactive rates for the full year of 2023 and from the second-year rate increases through the nine months ended September 30, 2024 are expected at this time to be reflected in the 2024 fourth quarter results.

American States Water Reveals Proposed Decision Adopting Settlement Agreement In Its Electric Utility General Rate Case

The Q1 earnings report for Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) was released on Wednesday, December 18, 2024 at 04:30 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Enerpac Tool Group missed estimated earnings by -2.0%, reporting an EPS of $0.4 versus an estimate of $0.41.
Revenue was up $3.23 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
Last quarter the company missed on EPS by $0.03 which was followed by a 1.0% drop in the share price the next day.
Here's a look at Enerpac Tool Group's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.53</td>
<td>0.47</td>
<td>0.36</td>
<td>0.32</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.50</td>
<td>0.47</td>
<td>0.36</td>
<td>0.39</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>156.70M</td>
<td>153.20M</td>
<td>141.10M</td>
<td>137.90M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>158.71M</td>
<td>150.39M</td>
<td>138.44M</td>
<td>141.97M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enerpac Tool Group <a href="https://www.benzinga.com/quote/EPAC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

EPAC

Recap: Enerpac Tool Group Q1 Earnings

Management

Grocery Outlet Appoints Christopher Miller As Executive Vice President And CFO, Effective January 6, 2025

Buybacks

Tri Pointe Homes Board Approves New Stock Repurchase Program Of Up To $250M Of Common Stock Through December 31, 2025

Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) reported quarterly earnings of $0.40 per share which missed the analyst consensus estimate of $0.41 by 2.44 percent. This is a 2.56 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $145.20 million which beat the analyst consensus estimate of $144.40 million by 0.55 percent. This is a 2.27 percent increase over sales of $141.97 million the same period last year.

Earnings Beats

Earnings Misses

Enerpac Tool Group Q1 2025 Adj EPS $0.40 Misses $0.41 Estimate, Sales $145.20M Beat $144.40M Estimate

Lennar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEN#NYSE">LEN</a>) reported quarterly earnings of $4.03 per share which missed the analyst consensus estimate of $4.16 by 3.12 percent. This is a 22.05 percent decrease over earnings of $5.17 per share from the same period last year. The company reported quarterly sales of $9.95 billion which missed the analyst consensus estimate of $10.08 billion by 1.35 percent. This is a 9.32 percent decrease over sales of $10.97 billion the same period last year.

Lennar Q4 2024 Adj EPS $4.03 Misses $4.16 Estimate, Sales $9.95B Miss $10.08B Estimate

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 15 years by 4.16% on an annualized basis producing an average annual return of 15.8%. Currently, Aon has a market capitalization of $76.25 billion. 
Buying $1000 In AON: If an investor had bought $1000 of AON stock 15 years ago, it would be worth $9,117.66 today based on a price of $352.58 for AON at the time of writing.
<h3>Aon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734557412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Aon Stock In The Last 15 Years

The Federal Reserve announced a widely anticipated 25-basis-point interest rate cut at its December meeting Wednesday, lowering the federal funds rate to a <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">range of 4.25% to 4.5%.</a>
The cut is the third consecutive reduction in borrowing costs following a 50-basis-point cut in September and a 25-basis-point move in November and brings rates to the lowest level since January 2023. 
Read Next: <a href="https://www.benzinga.com/general/market-summary/24/12/42535400/americans-bought-less-but-paid-more-says-peter-schiff-experts-digest-november-retail-sales-data">&#8216;Americans Bought Less But Paid More,&#8217; Says Peter Schiff: Experts Digest November Retail Sales Data</a>
Tthe Fed now projects two additional 0.25% rate cuts in 2025, a meaningful revision from the full percentage point of cuts expected in September. Markets reacted sharply lower following the Fed's decision with the SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) ending the session 2.98% lower at $586.28 and the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) closing 3.61% lower at $516.47.
Expert Ideas: Chris Zaccarelli, chief investment officer for Northlight Asset Management, said that markets are forward-looking and reacted to the Fed's 2025 projection and not the quarter-point cut that it also delivered. 
"Santa came early and dropped a 25-bps rate cut in the market's stocking but accompanied it with a note saying that there would be coal next year," Zaccarelli said.&nbsp;
Bill Adams, chief economist for Comerica Bank, said the Fed is reacting to the incoming Trump administration's policies, which it sees as most likely to boost growth and inflation, as well as tighten the job market. 
Trump does not have much control over the pace of rate cuts in the near term, Adams said, but "that could change in 2026 if President-elect Trump gets the Senate to confirm a new Fed chair who is more sympathetic to his policy goals."
Charlie Ripley, senior investment strategist for Allianz Investment Management, highlighted the growing concerns around inflation and the Fed's dot-plot, which shows shallower rate cuts ahead in both 2025 and 2026. 
"The main takeaway from today's Fed meeting was that inflation risks are back, and the Fed is clearly concerned," Ripley said.&nbsp;
"The Fed has been able to maneuver 100 basis points of cuts so far in this cycle but given the trajectory of the economy and the recent uptick of inflation, it is going to be more difficult for the Fed to provide basis to continue cutting rates at the same pace," he added.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42515463/nike-needs-a-turnaround-after-q2-results-are-released-this-week-will-new-ceo-just-do-it">Nike Needs A Turnaround After Q2 Results Are Released This Week: Will New CEO &#8216;Just Do It?&#8217;</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Macro Economic Events

'Santa Came Early' But Fed Brings 'Coal Next Year': Experts Weigh In On Interest Rate Cut, 2025 Projections

The company is in advanced discussions with various capital sources, and it works to finalize securing the capital necessary to move forward with its operations.
 &nbsp;

GOEV

Canoo  Furloughs 82 Employees, Both Salaried And Hourly, And Idling Its Factories In Oklahoma

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) reported financial results for the first quarter of fiscal 2025 after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/24/12/g42563530/micron-technology-inc-reports-results-for-the-first-quarter-of-fiscal-2025">of the report</a>.
Q1 Earnings: Micron reported first-quarter revenue of $8.71 billion, missing the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $8.72 billion. The company reported first-quarter adjusted earnings of $1.79 per share, beating analyst estimates of $1.76 per share, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Operating cash flow came in at $3.24 billion versus $3.41 billion in the prior quarter and $1.4 billion in the comparable quarter last year. Adjusted free cash flow was $112 million in the quarter, down from $323 million in the prior quarter. The company ended the quarter with $8.75 billion in cash, marketable investments and restricted cash.
&#8220;Micron delivered a record quarter, and our data center revenue surpassed&nbsp;50%&nbsp;of our total revenue for the first time,&#8221; said&nbsp;Sanjay Mehrotra, president and CEO of Micron.
&#8220;While consumer-oriented markets are weaker in the near term, we anticipate a return to growth in the second half of our fiscal year. We continue to gain share in the highest margin and strategically important parts of the market and are exceptionally well positioned to leverage AI-driven growth to create substantial value for all stakeholders.&#8221;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/24/12/42561975/whos-next-to-join-tesla-broadcom-in-1-trillion-club-over-50-say-the-worlds-biggest-retailer">Who&#8217;s Next To Join Tesla, Broadcom In $1 Trillion Club? Over 50% Say The World&#8217;s Biggest Retailer</a>
Outlook:&nbsp;Micron sees second-quarter revenue of $7.9 billion, plus or minus $200 million, versus estimates of $9 billion. The company expects second-quarter adjusted earnings of $1.43 per share, plus or minus 10 cents per share, versus estimates of $1.92 per share. 
Micron&#8217;s soft guidance appears to be weighing on shares after hours. Management will further discuss the quarter on a call with analysts and investors at 4:30 p.m. ET. 
MU Price Action: <a href="https://www.benzinga.com/quote/MU" target="_blank" rel="noreferrer noopener">Micron shares</a> were down 13.16% in after-hours, trading at $90.50 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">Fed Slashes Interest Rates By 0.25% As Predicted: December Dot Plot Flags Only 2 Potential Cuts In 2025</a></li>
</ul>
Photo: Courtesy of Micron.

After-Hours Center

Tech

Micron Q1 Earnings: Revenue Miss, EPS Beat, Soft Guidance Sinks Shares As Consumer Markets Turn 'Weaker' In Near Term

He succeeds John W. Somerhalder II, who will remain a director of the Board. Lisa Winston Hicks will remain the Board's Lead Independent Director.

FirstEnergy Says President And CEO Brian Tierney Has Been Elected By Board To Additional Role Of Chair, Effective Jan. 1, 2025

Worthington Steel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WS#NYSE">WS</a>) reported its Q2 earnings results on Wednesday, December 18, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Worthington Steel missed estimated earnings by -70.0%, reporting an EPS of $0.19 versus an estimate of $0.63.
Revenue was down $69.00 million from the same period last year.
<h3>Previous Earnings Records</h3>
During the previous quarter, the company missed on EPS by $0.04, leading to a 11.0% drop share price change the next day.

To track all earnings releases for Worthington Steel <a href="https://www.benzinga.com/quote/WS/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Worthington Steel Earnings Report: Q2 Overview

As a result of such extension, the Share Repurchase Program will expire on December 31, 2026. The Share Repurchase Program was previously scheduled to expire on December 31, 2024.&nbsp;
The other terms of the Share Repurchase Program remain unchanged, and as of December 18, 2024, the approximate dollar value of shares that may yet be purchased under the Share Repurchase Program is $1.4 billion.

EQT Board Approves Two-year Extension To Existing Share Repurchase Program, Which Program Was Originally Announced On December 13, 2021 - Filing

Dividends

ABCB

Ameris Bancorp Increases Quarterly Dividend From $0.15 To $0.20/Share

TriplePoint Venture Growth BDC Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) (the "Company" or "TPVG"), the leading financing provider to venture growth stage companies backed by a select group of venture capital firms in technology and other high growth industries, today announced the appointment of Mike L. Wilhelms as Chief Financial Officer (CFO) of the Company, effective as of January 6, 2025. Mr. Wilhelms will also serve as CFO of TriplePoint Capital LLC (TPC), TPVG's sponsor, and as CFO of TriplePoint Private Venture Credit Inc., TriplePoint Venture Lending Fund, LLC, TriplePoint Financial LLC and TriplePoint Advisers LLC. He will be based in Menlo Park, California.

TPVG

TriplePoint Venture Growth BDC Corp. Names Mike L. Wilhelms CFO, Effective As Of January 6, 2025

NYSE To Begin Delisting Proceedings Against Lion Electric Company

Assembly Biosciences closes $12.6M in equity financings

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMB – Research Report). The company's s...

H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)

Assembly Biosciences GAAP EPS of -$1.98 beats by $0.25

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Assembly Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/asmb-stock-quote/">ASMB</a>) just reported results for the second quarter of 2024.<ul><li>Assembly Biosciences reported earnings per share of -$1.98. This was above the analyst estimate for EPS of -$2.23.</li><li>The company reported revenue of $8.53 million.</li><li>This was 43.17% better than the analyst estimate for revenue of $5.96 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/asmb-stock-earnings-assembly-biosciences-for-q2-of-2024/">ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ASMB Stock Earnings: Assembly Biosciences Beats EPS, Beats Revenue for Q2 2024

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Thermo Fisher (TMO – Research Report), Nyxoah (NYXH ...

Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Nyxoah (NYXH) and Assembly Biosciences (ASMB)

H.C. Wainwright Sticks to Their Hold Rating for Assembly Biosciences (ASMB)

Capitulation in biotech is near, as well as a rally – Piper Sandler

Assembly Biosciences GAAP EPS of -$1.51, revenue of $6.85M

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company's shares closed last F...

H.C. Wainwright Keeps Their Hold Rating on Assembly Biosciences (ASMB)

Assembly Biosciences Inc ( ($ASMB) ) has released its Q3 earnings. Here is a breakdown of the information Assembly Biosciences Inc presented to its...

Assembly Biosciences Reports Q3 2024 Financials and Strategic Advances

CDNA

DTIL

EXEL

IBBQ

IDNA

NTRA

NYXH

PRAX

PTGX

SPRY

TRDA

Press Releases

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress™ 2024

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Announces $12.6 Million in Equity Financings

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

Comments

Assembly Biosciences

Assembly Biosciences (ASMB) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga